Baxter signs blood pact with Laboratoire Francais du Fractionnement et des Biotechnologies (LFB):
This article was originally published in Clinica
Executive Summary
French blood company Laboratoire Francais du Fractionnement et des Biotechnologies will distribute Baxter's HemAssist, an oxygen-carrying haemoglobin, in France. LFB has the monopoly on the production of blood derivatives from plasma collected in France. The two companies will invest Fr 200 million ($40 million) in a new production unit at LFB's Lille headquarters, for which Baxter will provide the production equipment. HemAssist is undergoing clinical trials on over 600 patients in the US and Europe and is expected to be launched by the beginning of 1998.